- BioXcel Therapeutics ( NASDAQ: BTAI ) said its oral medicine BXCL701 in combination with Merck's ( NYSE: MRK ) Keytruda showed encouraging response rate in patients with a type of prostate cancer in a phase 2a trial.
- The study evaluated BXCL701 in combination with Keytruda (pembrolizumab) in men with small cell neuroendocrine metastatic castration-resistant prostate cancer (SCNC).
- In the trial, 28 evaluable patients received the drug combination. The main goal of the study is a composite response rate, while secondary goals include duration of response, progression-free survival, overall survival, and biomarker evaluation.
- "We are pleased that BXCL701 in combination with pembrolizumab has demonstrated an encouraging response rate in this difficult-to-treat cancer with no currently approved FDA therapies," said Vincent O'Neill, chief R&D officer, OnkosXcel Therapeutics, a unit of BioXcel.
- The company added that full data will be presented at the 2023 ASCO Genitourinary Cancers Symposium in February.
- BTAI +3.38% to $24.46 premarket Jan. 11
For further details see:
BioXcel's BXCL701, Keytruda combo shows promise in mid-stage trial for prostate cancer